Catherine Masset

Efficacy and safety of sparsentan versus irbesartan in patients with IgA nephropathy (PROTECT): 2-year results from a randomised, active-controlled, phase 3 trial

Brad H. Rovin, Jonathan Barratt, Hiddo J.L. Heerspink et al. · The Lancet · 2023 · 224 citations · Full text

Sparsentan in patients with IgA nephropathy: a prespecified interim analysis from a randomised, double-blind, active-controlled clinical trial

Hiddo J.L. Heerspink, Jai Radhakrishnan, Charles E. Alpers et al. · The Lancet · 2023 · 203 citations · Full text

Glomerulonephritis, Active-controlled Clinical Trial, Renal Function +9

Physiological response from 18-25 years women to aerobic and anaerobic physical fitness tests at different periods during the menstrual cycle.

P. De Bruyn-Prevost, Catherine Masset, X Sturbois · PubMed · 1984 · 27 citations

Physical Activity, Oral Contraceptive, Reproductive Health +24

Sickle cell disease and COVID‐19: Atypical presentations and favorable outcomes

Marie‐Agnès Azerad, Firas Bayoudh, Thierry Weber et al. · eJHaem · 2020 · 17 citations · Full text

Critical Care Management, Red Blood Cell, Sickle Cell Disease +10